Ulysses Neuroscience Ltd is a patient-centric private R&D organization working together with pharmaceutical companies in order to accelerate drug discovery in neuropsychiatric (major depression, anorexia nervosa and schizophrenia) and neurodevelopmental (Fragile X Syndrome and CDKL5 Deficiency Disorders) diseases by using translation clinical and pre-clinical research. Our translational research investigates neurophysiological and molecular mechanisms leading to the synaptic pathology, microtubule dynamics dysregulation and neuroinflammatory events.